La vendita allo scoperto per NCS Multistage Holdings dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di NCS Multistage Holdings. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

NCS Multistage Holdings (NASDAQ:NCSM) Azioni, Report sulle vendite allo scoperto

NCS Multistage Holdings

NCS Multistage Holdings Inc provides products and support services that facilitate the optimization of oil and natural gas well completions and field development strategies. NCS provides its products and services to exploration and production companies for use in onshore wells, predominantly wells that have been drilled with horizontal laterals in unconventional oil and natural gas formations. The company's primary offering is its fracturing systems products and services, which enable efficient pinpoint stimulation: the process of individually stimulating each entry point into a formation targeted by an oil or natural gas well. Geographically, majority of revenue is generated from United States.

NCS Multistage Holdings, Inc. - Common Stock

NCS Multistage Holdings Inc

MicroStrategy Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) shares are moving in extended trading Monday after rallying about 13% during regular trading hours. Here&#8217;s what <a href="https://www.benzinga.com/trading-ideas/movers/24/11/42047385/microstrategy-shares-are-surging-monday-whats-going-on">you need to know</a>.
What To Know: After the market close on Monday, MicroStrategy announced a proposed private offering of $1.75 billion worth of its 0% convertible senior notes due 2029. 
The company will offer the shares in a private offering to qualified institutional buyers. MicroStrategy also plans to grant the initial purchasers a three-day period to purchase up to an additional $250 million worth of the notes. 
MicroStrategy said it intends to use the net proceeds from the offering to buy more Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>).
See Also: <a href="https://www.benzinga.com/general/social-media/24/11/42048594/trump-digs-deeper-into-cryptocurrency-bakkt-shares-soar-on-reported-interest-from-president-elects-media-company">Trump Digs Deeper Into Cryptocurrency? Bakkt Shares Soar On Reported Interest From President-Elect&#8217;s Media Company</a>
The offering follows a regulatory filing from Monday morning showing that MicroStrategy acquired approximately 51,780 Bitcoin between Nov. 11 and Nov. 17 for $4.6 billion in cash.
The purchases were funded using proceeds from the sales agreement the company entered into at the end of October. MicroStrategy said it had approximately $15.3 billion remaining under the sales agreement as of Nov. 17.
As of Sunday, MicroStrategy held a total of 331,200 Bitcoin purchased at an average price of approximately $49,874 per coin.
MicroStrategy co-founder and executive chairman Michael Saylor posted a <a href="https://x.com/saylor/status/1858247587951788410">poll on X</a> over the weekend asking whether Bitcoin would break through $100,000 by the end of the year. &#8220;Yes&#8221; was the answer of 85.6% of respondents.
MSTR Price Action: MicroStrategy shares initially traded closed Monday up almost 13%. The stock was down 0.64% in after-hours, trading at $382.33 at the time of writing, per <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42047066/goldman-sachs-to-spin-out-digital-assets-platform-amid-blockchain-push">Goldman Sachs To Spin Out Digital Assets Platform Amid Blockchain Push</a></li>
</ul>
Photo: Shutterstock.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

News

After-Hours Center

Movers

$BTC

MSTR

What's Going On With MicroStrategy Stock Monday?

The decision was made following the observation of certain in vivo preclinical toxicology findings.
These data have been shared with the U.S. Food and Drug Administration (FDA) and Incyte will work closely with the FDA to determine next steps.
&nbsp;
&nbsp;

INCY

Incyte To Pause Enrollment In Ongoing Phase 2 Study Of MRGPRX2 (INCB000262) In Chronic Spontaneous Urticaria;

LANC

Lancaster Colony To Acquire Sauce and Dressing Production Facility For ~$75M

NW Natural Holdings To Acquire  SiEnergy Operating From SiEnergy Capital Partners For $273M In Cash And The Assumption Of $152M In Debt

Icotrokinra (JNJ-2113), a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor, met its co-primary endpoints in patients with moderate to severe plaque psoriasis
74% of patients achieved clear or almost clear skin (IGA 0/1) at week 24
Comprehensive results are being prepared for presentation at upcoming medical congresses
SPRING HOUSE, Pa., Nov. 18, 2024 /PRNewswire/ -- Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) today announced positive topline results from <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4305031-1&amp;h=1172454155&amp;u=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT06095115&amp;a=ICONIC-LEAD">ICONIC-LEAD</a>a, a&nbsp;pivotal Phase 3 investigational study of icotrokinra (JNJ-2113), the first targeted oral peptide that selectively blocks the IL-23 receptor, in adults and adolescents 12 years of age and older with moderate to severe plaque psoriasis (PsO). The Phase 3 study met its co-primary endpoints of Psoriasis Area and Severity Index (PASI) 90b and Investigator's Global Assessment (IGA) of 0/1c response at week 16 and response rates continued to improve through week 24.1
Once daily icotrokinra showed significant skin clearance versus placebo in adults and adolescents with moderate to severe plaque psoriasis. At week 16, nearly two-thirds (64.7%) of patients treated with&nbsp;icotrokinra achieved IGA scores of 0/1 (clear or almost clear skin), and 49.6% achieved PASI 90, compared to 8.3% and 4.4% on placebo, respectively.1 Further increases in response rates continued to be observed at week 24, with 74.1% of patients treated with icotrokinra achieving IGA scores of 0/1, and 64.9%&nbsp;achieving PASI 90.1&nbsp;Safety data was found to be consistent with the Phase 2 FRONTIER 1 and 2 studies. A similar proportion of patients experienced adverse events (AEs) between icotrokinra and placebo, with 49.3% and 49.1% of participants experiencing a treatment emergent adverse event (TEAE) at week 16.1,2,3
Furthermore, positive topline results from the Phase 3 <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4305031-1&amp;h=4201851419&amp;u=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT06095102&amp;a=ICONIC-TOTAL">ICONIC-TOTAL</a>d&nbsp;study showed once daily icotrokinra met the primary endpoint of IGA of 0/1 at week 16 compared to placebo.4 Comprehensive results from ICONIC-LEAD and ICONIC-TOTAL are being prepared for presentation at upcoming medical congresses and will be shared with health authorities in planned submissions.

Biotech

General

Johnson & Johnson Announced Topline Results From ICONIC-LEAD, A Pivotal Phase 3 Investigational Study Of Icotrokinra, The First Targeted Oral Peptide That Selectively Blocks The IL-23 Receptor, In Adults And Adolescents 12 Years Of Age And Older With Moderate To Severe Plaque Psoriasis; Met Its Co-Primary Endpoints In Patients With Moderate To Severe Plaque Psoriasis; 74% Of Patients Achieved Clear Or Almost Clear Skin At Week 24

Guidance

Archer-Daniels Midland Sees FY24 Adj. EPS $4.50-$5.00 Vs $4.60 Est.

Berquist, who succeeds Andy Tometich as Chief Executive Officer&nbsp;and President, most recently served as Executive Vice President and Chief Commercial Officer for Quaker Houghton.

Management

Quaker Houghton Board Appoints Joseph Berquist As CEO And President, And A Member Of Board, Effective Immediately

Archer-Daniels Midland (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADM#NYSE">ADM</a>) reported quarterly earnings of $1.09 per share which missed the analyst consensus estimate of $1.25 by 12.8 percent. The company reported quarterly sales of $19.937 billion which missed the analyst consensus estimate of $21.345 billion by 6.59 percent. This is a 8.10 percent decrease over sales of $21.695 billion the same period last year.

Earnings

Earnings Misses

Archer-Daniels Midland Q3 2024 Adj. EPS $1.09 Misses $1.25 Estimate, Sales $19.937B Miss $21.345B Estimate

Wendy's Appoints Ken Cook As CFO, Effective Dec. 2

Piper Sandler analyst Christopher Raymond upgrades Aclaris Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>) from Neutral to Overweight and raises the price target from $3 to $13.

Upgrades

Price Target

Analyst Ratings

ACRS

Piper Sandler Upgrades Aclaris Therapeutics to Overweight, Raises Price Target to $13

Symbotic Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYM#NASDAQ">SYM</a>) reported its fourth-quarter results after Monday's closing bell. Here's a look at the <a href="https://www.benzinga.com/pressreleases/24/11/g42048131/symbotic-reports-fourth-quarter-and-fiscal-year-2024-results">details from the report.&nbsp;</a>
The Details:&nbsp;Symbotic reported quarterly earnings of five cents per share, which beat the analyst consensus estimate of three cents. Quarterly revenue came in at $576.76 million, which beat the analyst consensus estimate of $470.27 million and is an increase over sales of $391.88 million from the same period last year.
Read More: <a href="https://www.benzinga.com/etfs/24/11/42044642/trump-appears-frustrated-as-elon-musk-chimes-in-on-treasury-secretary-adds-more-names-to-a-list-of-potential-picks">Trump Appears &#8216;Frustrated&#8217; As Elon Musk Chimes In On Treasury Secretary, Adds More Names To Short List&nbsp;</a>
&#8220;I&#8217;m pleased with our performance this year, as our focus on innovation and customer success has delivered robust growth. This year&#8217;s results, driven by the hard work and dedication of our team, underscore the strength of our long-term strategy and commitment to driving sustainable, long-term growth for our customers, shareholders, and employees,&#8221; said Rick Cohen, CEO of Symbotic. 
Outlook:&nbsp;For the first quarter of fiscal 2025, Symbotic expects revenue of $495 million to $515 million, versus the $495.73 million estimate, and adjusted EBITDA of $27 million to $31 million.
SYM Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Symbotic shares are up 23.21% after-hours at $37.44 at the time of publication Monday.&nbsp;
Read More:  • <a href="https://www.benzinga.com/24/11/42047989/walmart-q3-earnings-preview-will-eps-beat-streak-continue-analysts-says-retailer-should-remain-a-core-holding">Will Walmart&#8217;s Streak Of Earnings Beats Continue Tuesday? Analysts Say Retailer A &#8216;Core Holding&#8217;</a>
Photo: Courtesy of Symbotic, Inc.

Symbotic Stock Rallies After Strong Q4 Results: Details

AMD Announces Darla Smith Resigns As Chief Accounting Officer, To Remain VP Until January 2025; Philip Carter Appointed As New Chief Accounting Officer

GBDC

Golub Capital BDC Reveals Series Of Debt Funding Structure Initiatives Expected To Reduce  Prospective Borrowing Costs And Provide Investment Flexibility

Investors and speculators are gearing up for Nvidia Corp.&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) earnings report on Wednesday, an event that&#8217;s expected to send ripples, if not tidal waves, <a href="https://www.benzinga.com/markets">across the U.S. stock market. </a>
If the options market is right, Nvidia's results could spark moves in the S&amp;P 500 index – as tracked by the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) – larger than those typically triggered by key economic data like the employment and inflation reports.
Nvidia's dominance in the AI-driven technology trade has turned its earnings into a barometer for overall market sentiment, and its influence on the stock market is unparalleled.
Over the past year, Nvidia accounted for 20% of the S&amp;P 500's total returns and Bank of America's derivatives analyst Gonzalo Asis didn't mince words: &#8220;It remains the most dominant stock in the market… expected to drive nearly 25% of the S&amp;P 500&#8217;s EPS growth in 3Q.&#8221;
In essence, whether Nvidia beats or misses expectations, the ripple effects will likely extend far beyond its ticker.
<h3 class="wp-block-heading">S&amp;P 500 Implied Move Is Higher Than Inflation Or Jobs Data</h3>
The options market implies a potential 1.05% move in the S&amp;P 500—higher than what traders expect from next month's Non-Farm Payroll (NFP) data, Consumer Price Index (CPI) print, and in line with the Federal Reserve&#8217;s December meeting.
&#8220;Options are assigning more broad-market risk around NVDA earnings than around next month&#8217;s NFP and CPI days, and as much as the Dec FOMC,&#8221; the analyst noted.
For Nvidia shares themselves, the implied one-day move is even more eye-popping: 12.5%.
&#8220;We remain cautious of fragility risks in single names around earnings, but NVDA hedges themselves are not particularly cheap relative to how much the stock has reacted to results in the last two years,&#8221; Assis wrote.
The analyst also warned that the recent easing of post-election euphoria and heightened single-stock fragility can be reasons for traders to hedge against potential market turbulence if Nvidia disappoints.
<h3 class="wp-block-heading">A Strategy For Hedging The Nasdaq Impact</h3>
For traders seeking to hedge the broader market risks tied to Nvidia&#8217;s performance, Bank of America recommended an option strategy using put spreads on the Nasdaq-100 ETF, the Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>). Specifically, the QQQ 22Nov 490-480 put spreads are priced at $2 and could offer a 5x payout if the Nasdaq-100 falls by roughly 3.3% this week.
Despite the potential need for hedges, the bank also noted that hedging NVDA earnings directly is not cheap, considering how significantly the stock has reacted to its last few earnings reports.
<h3 class="wp-block-heading">Historical Nvidia Earnings Data</h3>
Data from <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent111824&amp;t=be2bearmibe3na1">Benzinga Pro</a> shows that over the last 12 quarters, Nvidia has exceeded earnings-per-share (EPS) expectations 10 times and missed revenue expectations only once. 
On average, Nvidia shares moved 5.3% in the single trading day following its earnings release.
The largest 1-day gain followed its first quarter 2024 earnings, when the stock surged 24.4%, while the worst reaction occurred after fourth quarter 2024 results, with a decline of 7.6%. 
Here's a snapshot of the company's recent earnings performance:
<figure class="wp-block-table is-style-stripes"> 
<table>
<thead>
<tr>
<th>Fiscal Quarter</th>
<th>Date Announced</th>
<th>Surprise % EPS</th>
<th>Surprise % Revenue</th>
<th>1-Day % NVDA Move</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q2-2025</td>
<td>8/28/24</td>
<td>6.25%</td>
<td>4.73%</td>
<td>-6.38%</td>
</tr>
<tr>
<td>Q1-2025</td>
<td>5/22/24</td>
<td>2.86%</td>
<td>5.66%</td>
<td>9.32%</td>
</tr>
<tr>
<td>Q4-2024</td>
<td>2/21/24</td>
<td>11.45%</td>
<td>7.19%</td>
<td>16.40%</td>
</tr>
<tr>
<td>Q3-2024</td>
<td>11/21/23</td>
<td>19.64%</td>
<td>12.39%</td>
<td>-2.46%</td>
</tr>
<tr>
<td>Q2-2024</td>
<td>8/23/23</td>
<td>29.19%</td>
<td>20.38%</td>
<td>0.10%</td>
</tr>
<tr>
<td>Q1-2024</td>
<td>5/24/23</td>
<td>18.48%</td>
<td>10.31%</td>
<td>24.37%</td>
</tr>
<tr>
<td>Q4-2023</td>
<td>2/22/23</td>
<td>8.64%</td>
<td>0.68%</td>
<td>14.02%</td>
</tr>
<tr>
<td>Q3-2023</td>
<td>11/16/22</td>
<td>-15.94%</td>
<td>2.79%</td>
<td>-1.46%</td>
</tr>
<tr>
<td>Q2-2023</td>
<td>8/24/22</td>
<td>-59.20%</td>
<td>-17.23%</td>
<td>4.01%</td>
</tr>
<tr>
<td>Q1-2023</td>
<td>5/25/22</td>
<td>5.43%</td>
<td>2.07%</td>
<td>5.16%</td>
</tr>
<tr>
<td>Q4-2022</td>
<td>2/16/22</td>
<td>8.20%</td>
<td>3.01%</td>
<td>-7.56%</td>
</tr>
<tr>
<td>Q3-2022</td>
<td>11/17/21</td>
<td>6.36%</td>
<td>4.00%</td>
<td>8.25%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Data: Benzinga Pro</figcaption></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/24/11/42042411/inflation-could-surge-to-3-if-trump-applies-universal-tariffs-goldman-sachs">Inflation Could Surge To 3% If Trump Applies Universal Tariffs: Goldman Sachs</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Equities

Broad U.S. Equity ETFs

Previews

Options

Econ #s

Economics

Federal Reserve

Tech

ETFs

NVDA

Why Nvidia Earnings May Trigger Massive S&P 500 Volatility

Current CEO Lou Haddad will retire at the end of 2024 but will retain the role of Executive Chairman of the Company's Board of Directors. Additionally, the Board of Directors expects to appoint Tibbetts to the Board of Directors upon his elevation to Chief Executive Officer.

Armada Hoffler Names Shawn Tibbetts As CEO, Effective January 1, 2025; Current CEO Lou Haddad To Retain The Role Of Executive Chairman

-The New York Stock Exchange ("NYSE", the "Exchange") announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the common stock of Spirit Airlines, Inc. (the "Company") — ticker symbol SAVE — from the NYSE. Trading in the Company's common stock will be suspended immediately.
NYSE Regulation reached its decision that the Company is no longer suitable for listing pursuant to NYSE Listed Company Manual Section 802.01D after the Company's November 18, 2024 press release and Form 8-K disclosures that the Company has commenced a prearranged chapter 11 process in the United States Bankruptcy Court for the Southern District of New York. In reaching its delisting determination, NYSE Regulation notes the Company disclosed that all of the Company's existing common stock and other equity interests will be cancelled without any distributions to the holders of such common stock and other equity interests on account thereof.
The Company has a right to a review of this determination by a Committee of the Board of Directors of the Exchange. The NYSE will apply to the Securities and Exchange Commission to delist the common stock upon completion of all applicable procedures, including any appeal by the Company of the NYSE Regulation staff's decision.

SAVE

NYSE To Commence Delisting Proceedings Against Spirit Airlines, Effective Immediately

Healthpeak Properties Raises FY24 AFFO From $1.56-$1.58 To $1.57-$1.59

MCHP

Microchip Technology Announces Ganesh Moorthy Is Retiring As CEO, President And Board Member; Steve Sanghi Appointed Interim CEO

Spyre Therapeutics, Inc. ("Spyre" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYRE#NASDAQ">SYRE</a>), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy and convenience in the treatment of inflammatory bowel disease ("IBD"), today announced that it has commenced an underwritten public offering of up to $200.0 million of shares of its common stock or, in lieu of issuing common stock to certain investors, pre-funded warrants to purchase shares of its common stock. In addition, the Company is expected to grant the underwriters of the offering an option for a period of 30 days to purchase up to an additional $30.0 million of shares of common stock at the public offering price, less the underwriting discount. All of the shares of common stock and pre-funded warrants in the offering will be sold by Spyre.&nbsp;
The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Jefferies LLC, Goldman Sachs &amp; Co. LLC, Evercore Group L.L.C., and Guggenheim Securities, LLC are acting as the joint book-running managers for the proposed offering. LifeSci Capital LLC is acting as lead manager for the proposed offering.

Offerings

SYRE

Spyre Therapeutics Announces Proposed $200M Public Offering Of Its Common Stock And Pre-Funded Warrants

WIIM

OMCL

Omnicell shares are trading lower after the company announced a proposed private placement of $150 million in convertible senior notes.

NCS Multistage Holdings, Inc. (NCSM) Q1 2024 Earnings Call Transcript

NCS Multistage files for $200M common stock offering by selling stockholders

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
NCS Multistage Holdings (NASDAQ:<a href="https://investorplace.com/stock-quotes/ncsm-stock-quote/">NCSM</a>) just reported results for the second quarter of 2024.<ul><li>NCS Multistage Holdings reported earnings per share of -$1.03. This was above the analyst estimate for EPS of -$1.23.</li><li>The company reported revenue of $29.69 million.</li><li>This was 4.18% better than the analyst estimate for revenue of $28.50 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/07/ncsm-stock-earnings-ncs-multistage-holdings-for-q2-of-2024/">NCSM Stock Earnings: NCS Multistage Holdings Beats EPS, Beats Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

NCSM Stock Earnings: NCS Multistage Holdings Beats EPS, Beats Revenue for Q2 2024

NCS Multistage Holdings Non-GAAP EPS of -$1.03, revenue of $29.7M

NCS Multistage Holdings GAAP EPS of -$1.21, revenue of $29.7M

NCS Multistage Holdings, Inc. (NCSM) Q2 2024 Earnings Call Transcript

NCS Multistage Holdings GAAP EPS of $1.60 beats by $0.33, revenue of $44M beats by $1.2M

NCS Multistage Holdings, Inc. 2024 Q3 - Results - Earnings Call Presentation

Ncs Multistage Holdings ( ($NCSM) ) has released its Q3 earnings. Here is a breakdown of the information Ncs Multistage Holdings presented to its i...

NCS Multistage Holdings: Q3 2024 Financial Performance

NCS Multistage Holdings, Inc. (NCSM) Q3 2024 Earnings Call Transcript

NCSM

Commodities

Small Cap

Press Releases

Presentation Times and Schedule for Participating Companies Now Posted on the Conference Website for 29th Annual EnerCom Denver - The Energy Investment Conference

NCS Multistage Holdings, Inc. Schedules Second Quarter 2024 Earnings Release and Conference Call

Investor One-on-One Meeting Requests Open for 29th Annual EnerCom Denver - The Energy Investment Conference, to be held August 18-21, 2024 in Denver, Colorado

NCS Multistage Holdings, Inc. Announces Second Quarter 2024 Results

EnerCom's 29th Annual Energy Investment Conference is Set to be Held August 18-21, 2024 in Denver, Colorado

NCS Multistage Holdings, Inc. Schedules Third Quarter 2024 Earnings Release and Conference Call

Presenting on the Emerging Growth Conference 76 Day 1 on October 30 Register Now

Presenting on the Emerging Growth Conference 76 Day 2 on October 31 Register Now

NCS Multistage Holdings, Inc. Announces Third Quarter 2024 Results

NRx Pharmaceuticals added to Emerging Growth Conference 76 on October 31 and Update to Schedule

Comments

NCS Multistage Holdings

Vendite allo scoperto

NCS Multistage Holdings (NASDAQ:NCSM) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO